Age: 44.0
Sex: F
Vaccine: COVID19
Symptoms: Nausea, Photophobia, Tonsillar hypertrophy
Clinical narrative: significant cervical, auricular, occipital lymphadenopathy; bilateral L>R, w/enlarged R tonsilar, submental lymph; dysphagia; burning diffuse headache with photo phobia; burning diffuse headache with photo phobia; nausea; w/associated migraine symptoms R temporal; Booster; This is a spontaneous report received from a contactable reporter(s) (Other HCP). The reporter is the patient.  A 44 year-old female patient received bnt162b2 (BNT162B2), administered in arm left, administration date 20Oct2021 12:00 (Lot number: fh8020) at the age of 44 years as dose 3 (booster), single for covid-19 immunisation. Relevant medical history included: "migraine" (unspecified if ongoing), notes: Other medical history: migraine, hashimoto, rocky mountain spotted fever; "hashimoto" (unspecified if ongoing), notes: Other medical history: migraine, hashimoto, rocky mountain spotted fever; "rocky mountain spotted fever" (unspecified if ongoing), notes: Other medical history: migraine, hashimoto, rocky mountain spotted fever. The patient's concomitant medications were not reported. Past drug history included: Haldol, reaction(s): "Known allergies: Haldol", notes: Known allergies: Haldol. Vaccination history included: Bnt162b2 (Prev dose product: COVID 19, Prev dose brand: Pfizer, Prev dose brand unknown: False, Prev dose lot unknown: True, Prev dose lot unknown reason: Unable to locate or read the details, Prev dose administration date: 05Feb2021, Prev dose dose number: 2, Prev dose vaccine location: Left arm), administration date: 05Feb2021, when the patient was 43 years old, for Covid-19 Immunization; Bnt162b2 (Prev dose product: COVID 19, Prev dose brand: Pfizer, Prev dose brand unknown: False, Prev dose lot unknown: True, Prev dose lot unknown reason: Unable to locate or read the details, Prev dose administration date: 08Jan2021, Prev dose administration time: 05:00 PM, Prev dose dose number: 1, Prev dose vaccine location: Left arm), administration date: 08Jan2021, when the patient was 43 years old, for Covid-19 Immunization. The following information was reported: IMMUNISATION (non-serious) with onset 20Oct2021 12:00, outcome "unknown", described as "Booster"; LYMPHADENOPATHY (non-serious) with onset 22Oct2021, outcome "recovering", described as "significant cervical, auricular, occipital lymphadenopathy"; TONSILLAR HYPERTROPHY (non-serious) with onset 22Oct2021, outcome "recovering", described as "bilateral L>R, w/enlarged R tonsilar, submental lymph"; DYSPHAGIA (non-serious) with onset 22Oct2021, outcome "recovering", described as "dysphagia"; HEADACHE (non-serious), PHOTOPHOBIA (non-serious) all with onset 22Oct2021, outcome "recovering" and all described as "burning diffuse headache with photo phobia"; NAUSEA (non-serious) with onset 22Oct2021, outcome "recovering", described as "nausea"; MIGRAINE (non-serious) with onset 22Oct2021, outcome "recovering", described as "w/associated migraine symptoms R temporal". The events "significant cervical, auricular, occipital lymphadenopathy", "bilateral l>r, w/enlarged r tonsilar, submental lymph", "dysphagia", "burning diffuse headache with photo phobia", "burning diffuse headache with photo phobia", "nausea" and "w/associated migraine symptoms r temporal" were evaluated at the physician office visit. Therapeutic measures were taken as a result of lymphadenopathy, tonsillar hypertrophy, dysphagia, headache, photophobia, nausea, migraine.  Additional Information: Prior vaccination within 4 weeks was reported as none. Prior to vaccination patient was not diagnosed with COVID-19 and since the vaccination, the patient had not been tested for COVID-19. Treatment for adverse event was reported as high dose prednisone, chiropractic/massage.  No follow-up attempts are possible. No further information is expected.